ArticleACR open rheumatology2026
Impaired Generation of High-Affinity Memory B Cells and Neutralizing Antibodies Against SARS-CoV-2 in Adolescents and Young Adults With Juvenile Idiopathic Arthritis Treated With Tumor Necrosis Factor Inhibitors.
Article in ACR open rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectiveWe evaluated the immunogenicity of SARS-CoV-2 mRNA vaccines in patients with juvenile idiopathic arthritis (JIA), focusing on the generation of spike-specific memory B cells (MBCs) and of neutralizing antibodies, and assessed the impact of disease-modifying antirheumatic drugs, particularly tumor necrosis factor inhibitors (TNFi).
methodsThis study enrolled 35 adolescent and young adult patients with JIA. Data concerning disease characteristics and SARS-CoV-2 vaccination and infection were collected. We analyzed the frequency of low-affinity spike-specific and high-affinity spike-specific MBCs by flow cytometry. We measured total anti-spike antibodies levels using a chemiluminescence microparticle immunoassay and assessed neutralizing antibody titers with a microneutralization assay.
resultsPatients with JIA showed a reduced frequency of high-affinity MBCs compared to controls, with a notably poorer response among those receiving TNFi treatment. Additionally, their ability to bind the Omicron variant was significantly lower, particularly among TNFi-treated patients. SARS-CoV-2 infection alone was not able to generate high-affinity MBCs and neutralizing antibodies in patients with JIA. After receiving three vaccine doses, 43% of patients with JIA exhibited a reduced frequency of high-affinity MBCs and neutralizing antibodies.
conclusionPatients with JIA undergoing treatment with TNFi demonstrated a diminished immunogenic response to SARS-CoV-2 vaccination, with lower frequencies of high-affinity MBCs and decreased neutralizing antibody titers. These findings underscore the need for customized vaccination protocols, including the potential use of booster doses, to enhance immunoprotection in this group. Additionally, the development of reliable biomarkers to distinguish between patients with and without adequate protective immunity is imperative to refine therapeutic interventions and ensure optimal patient outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.